ADDRI

The Asbestos Diseases Research Institute (ADRI), often referred to as ADDRI, is a premier Australian research organization dedicated to improving the diagnosis and treatment of asbestos-related diseases, particularly malignant mesothelioma. Established in 2009 and based at the Bernie Banton Centre in Sydney, the institute focuses on translational research, clinical trials, and public health advocacy. ADRI is notable for developing the TargomiR platform, an innovative RNA-based therapy that utilizes microRNA mimics delivered via targeted minicells. The institute collaborates extensively with global academic and clinical partners to advance genomic and proteomic understanding of thoracic cancers. Beyond drug development, ADRI provides essential support services and education for patients and healthcare professionals affected by asbestos exposure.